Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues	$ 7,922,667	$ 7,489,479
Cost of revenues	8,042,265	6,228,256
Research and development	3,462,905	5,876,178
Selling, general, and administrative	5,949,180	6,458,331
Total operating costs and expenses	17,454,350	18,562,765
Operating loss	(9,531,683)	(11,073,286)
Other income (expense):
Other income (expense), net	(44,395)	5,685
Interest expense	(167,715)	(926,817)
Nonoperating Income (Expense), Total	(212,110)	(921,132)
Loss before provision for income taxes and noncontrolling interests	(9,743,793)	(11,994,418)
Provision for income taxes	49,531	53,378
Net loss	(9,793,324)	(12,047,796)
Less - loss attributable to noncontrolling interests	(433,497)	(66,879)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (9,359,827)	$ (11,980,917)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (1.12)	$ (2.09)
Weighted average common shares outstanding	8,386,903	5,738,044